Bolivia presents three distinct health challenge zones corresponding to altitude. The Altiplano and cities above 3,000 meters create immediate physiological stress through reduced oxygen availability. The intermediate Yungas valleys between 1,000 and 3,000 meters shift concerns toward tropical disease vectors. The lowland Amazon Basin and Chaco below 1,000 meters concentrate mosquito-borne illness risk and heat-related conditions. La Paz sits at 3,640 meters while the adjacent city of El Alto reaches 4,150 meters, making them among the highest urban centers globally where visitors will spend consecutive nights. Sucre at 2,810 meters and Cochabamba at 2,558 meters occupy the intermediate band. Santa Cruz de la Sierra at 416 meters and Trinidad at 236 meters represent the lowland exposure profile. Medical infrastructure quality drops sharply outside departmental capitals, and evacuation times from remote areas like Madidi National Park or the Salar de Uyuni exceed twelve hours to facilities with advanced capabilities.
Acute mountain sickness affects between 25 and 50 percent of travelers arriving directly at La Paz's El Alto International Airport at 4,061 meters. Symptoms manifest within six to twelve hours: headache, nausea, fatigue, difficulty sleeping, dizziness. The condition results from hypobaric hypoxia—atmospheric pressure at 4,000 meters provides approximately 60 percent of the oxygen molecules per breath compared to sea level. Acclimatization requires physiological adjustment over 48 to 72 hours as the body increases red blood cell production and alters breathing patterns. Pre-travel conditioning provides no protection; physical fitness does not prevent altitude illness. The only evidence-based prevention involves gradual ascent—sleeping no more than 300 to 500 meters higher each night once above 3,000 meters. Most visitors cannot follow this protocol when flying into La Paz. Acetazolamide 125 milligrams twice daily starting 24 hours before ascent reduces incidence but carries side effects including frequent urination and altered taste sensation. The medication works by acidifying blood to stimulate breathing. This is infrastructure information; consult a physician for prescription decisions.
High-altitude pulmonary edema and high-altitude cerebral edema represent life-threatening progressions occurring in approximately 1 to 2 percent of people ascending above 3,500 meters. Pulmonary edema involves fluid accumulation in lung tissue, producing shortness of breath at rest, cough with pink frothy sputum, extreme fatigue, and chest tightness. Cerebral edema manifests as severe headache unresponsive to medication, ataxia (stumbling gait), confusion, and altered consciousness. Both conditions require immediate descent—dropping even 500 to 1,000 meters produces improvement within hours. Dexamethasone 8 milligrams initial dose can temporize cerebral edema during evacuation. Nifedipine 30 milligrams extended-release addresses pulmonary edema acutely. Portable hyperbaric chambers exist at some trekking agencies and high-altitude hotels. The nearest hyperbaric facilities with continuous staffing operate in La Paz at Clínica del Sur and Clínica Alemana. Direct all medical decisions to a physician.
Yellow fever transmission occurs in departments below 2,300 meters including Beni, Pando, Santa Cruz, Cochabamba, La Paz, and Tarija. The Aedes and Haemagogus mosquitoes transmit the flavivirus primarily in forested regions. Bolivia requires proof of yellow fever vaccination for travelers arriving from countries with transmission risk. The vaccine contains live attenuated virus and requires administration at least ten days before entry to allow antibody development. Single-dose protection appears lifelong based on studies published in 2013 and 2016, though some countries still request revaccination after ten years. The vaccine carries contraindications for people over 60 years receiving first dose, immunocompromised individuals, pregnant women, and those with egg or gelatin allergies. Serious adverse events occur in approximately 1 per 250,000 doses. The International Certificate of Vaccination or Prophylaxis documents administration. Consult a physician regarding individual risk-benefit assessment.
Dengue transmission occurs year-round below 2,000 meters with peak incidence during the rainy season from November through March. Bolivia reported 9,214 confirmed dengue cases in 2022 and 17,968 cases in 2023 according to the Pan American Health Organization. Santa Cruz department accounts for 60 to 70 percent of national cases. The Aedes aegypti mosquito transmits four dengue virus serotypes through daytime biting, with peak activity two hours after sunrise and several hours before sunset. Primary infection produces fever, severe headache, pain behind the eyes, joint and muscle pain, rash, and mild bleeding manifestations. Secondary infection with a different serotype carries 2 to 5 percent risk of severe dengue involving plasma leakage, fluid accumulation, respiratory distress, severe bleeding, or organ impairment. No antiviral treatment exists; management involves fluid replacement and monitoring. No vaccine is currently recommended for travelers. Prevention relies entirely on mosquito bite avoidance through DEET-containing repellents at 20 to 30 percent concentration, permethrin-treated clothing, and accommodations with screened windows or air conditioning. Aedes aegypti breeds in artificial water containers within human habitations.
Malaria transmission persists in rural areas of the Amazon Basin departments—Pando, Beni, and northern La Paz—below 2,500 meters. The Bolivian National Malaria Program reported 3,847 confirmed cases in 2021, with Plasmodium vivax accounting for 89 percent and Plasmodium falciparum representing 11 percent. The municipality of Guayaramerín in Beni department along the Brazilian border consistently reports the highest incidence. Anopheles darlingi serves as the primary vector, biting between dusk and dawn. Chloroquine-resistant Plasmodium falciparum exists in all transmission zones. Atovaquone-proguanil, doxycycline, or mefloquine provide appropriate chemoprophylaxis options depending on individual contraindications and side effect tolerance. No prophylaxis achieves 100 percent protection; mosquito avoidance remains essential. Urban areas including La Paz, Sucre, Cochabamba, and Santa Cruz de la Sierra have no transmission risk. Travelers visiting only the Altiplano, Salar de Uyuni, Lake Titicaca, Potosí, or Sucre do not require malaria prophylaxis. This is infrastructure information; consult a physician for prescription decisions regarding specific medications and individual risk assessment.
Zika virus, chikungunya, and Mayaro virus circulate in the same lowland regions and through the same Aedes mosquito vectors as dengue. Bolivia confirmed Zika transmission during the 2016-2017 epidemic with 1,950 suspected cases reported in 2016. Transmission has decreased substantially but remains possible. Zika infection during pregnancy causes microcephaly and other severe brain defects. No vaccine or preventive medication exists. Pregnant women should consult physicians regarding travel to transmission areas. Chikungunya produces high fever and severe joint pain that can persist for months. Mayaro virus causes similar symptoms and occurs primarily in forested Amazon regions. All three depend on identical mosquito avoidance measures as dengue prevention.
Chagas disease, caused by the parasite Trypanosoma cruzi, maintains endemic presence throughout Bolivia with highest rates in the departments of Cochabamba, Chuquisaca, Tarija, and Santa Cruz. The World Health Organization estimated Bolivia's prevalence at 6.1 percent of the population in 2010, representing approximately 600,000 infected individuals—the highest national prevalence rate globally. The triatomine bug, called vinchuca locally, transmits the parasite through defecation during blood-feeding at night. The bugs inhabit cracks in adobe walls and thatched roofs in rural housing. Acute infection produces fever, swelling at the bite site, and sometimes facial edema. Chronic infection develops in 30 to 40 percent of cases over years to decades, causing cardiac complications including arrhythmias and heart failure, or digestive tract enlargement. Short-term travelers staying in conventional hotels face negligible risk. Risk increases for those sleeping in traditional rural housing in endemic areas. Protective measures include bed nets, inspection of sleeping areas, and avoidance of obviously infested structures. No vaccine exists.
Typhoid fever transmission occurs through contaminated food and water across Bolivia. The bacterium Salmonella typhi spreads via the fecal-oral route.